November 18, 2025

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Conexiant

November 18, 2025

Why Do Some Struggle to Hear in Noise?

Researchers examine how lower intellectual ability is linked to poorer multitalker speech perception in neurodivergent individuals with normal hearing. 

Conexiant

November 18, 2025

Oligonucleotides: Synthesis and Manufacturing Hurdles

As oligonucleotides gain traction, manufacturing capabilities and analytical systems are being retooled to meet new demands for scale, purity, and efficiency.

The Analytical Scientist

November 17, 2025

‘Patent Dance’ Delays Biosimilars Despite FDA Shift

The FDA moves to speed biosimilar approvals, but rising patent barriers may still delay lower-cost alternatives.

Conexiant

November 14, 2025

Epilepsy Trends: Do Long-Term Outcomes Improve?

Researchers found seizure reductions over time in patients with focal treatment-resistant epilepsy.

Conexiant

November 14, 2025

Long-Term Data Reveal NGS Adoption Trend in LDTs

An analysis of New York State test submissions from 2010 to 2024, presented at AMP 2025, shows steady growth of NGS panels, WES, WGS, and cfDNA testing.

Conexiant

November 13, 2025

Allergies May Increase Surgical Risk

Researchers show that patients with allergies face higher postoperative risks.

Conexiant

November 13, 2025

‘FDA Said Yes, Despite Inconclusive Evidence’

The FDA’s authorization of the Q-Collar is under scrutiny after researchers identified duplicated data, altered study endpoints, and unsubstantiated “brain protection” claims.

Conexiant

November 12, 2025

AVM Hemorrhage Risk: Is It Time to Rethink the Data?

Researchers redefine the true hemorrhage risk of unruptured brain arteriovenous malformations.

Conexiant